dibenzothiazepines

Summary

Top Publications

  1. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
  2. ncbi Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study
    John W Devlin
    Northeastern University School of Pharmacy, Boston, MA, USA
    Crit Care Med 38:419-27. 2010
  3. ncbi A randomized controlled trial of quetiapine versus placebo in the treatment of delirium
    Tayyeb A Tahir
    Department of Liaison Psychiatry, University Hospital of Wales, Cardiff and Vale University Health Board, Heath Park, Cardiff, UK
    J Psychosom Res 69:485-90. 2010
  4. ncbi Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes
    L Xiao
    Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, SK, Canada
    Mol Psychiatry 13:697-708. 2008
  5. ncbi Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex
    Satoshi Yamamura
    Department of Psychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, 2 174 Edobashi, Tsu, Mie, 514 8507, Japan
    Psychopharmacology (Berl) 206:243-58. 2009
  6. ncbi Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial
    Michael Liebowitz
    Department of Psychiatry, Columbia University, New York, New York 10128, USA
    Depress Anxiety 27:964-76. 2010
  7. ncbi Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors
    Yuko Tanibuchi
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1 8 1 Inohana, Chiba 260 8670, Japan
    Eur Neuropsychopharmacol 19:861-7. 2009
  8. ncbi Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Canada
    Eur Neuropsychopharmacol 15:573-85. 2005
  9. ncbi Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study
    Alexander McIntyre
    Department of Psychiatry, Penticton Regional Hospital, Penticton, British Columbia, Canada
    Depress Anxiety 24:487-94. 2007
  10. ncbi Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
    Rene S Kahn
    Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, Netherlands
    Lancet 371:1085-97. 2008

Detail Information

Publications242 found, 100 shown here

  1. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  2. ncbi Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study
    John W Devlin
    Northeastern University School of Pharmacy, Boston, MA, USA
    Crit Care Med 38:419-27. 2010
    ..To compare the efficacy and safety of scheduled quetiapine to placebo for the treatment of delirium in critically ill patients requiring as-needed haloperidol...
  3. ncbi A randomized controlled trial of quetiapine versus placebo in the treatment of delirium
    Tayyeb A Tahir
    Department of Liaison Psychiatry, University Hospital of Wales, Cardiff and Vale University Health Board, Heath Park, Cardiff, UK
    J Psychosom Res 69:485-90. 2010
    ..Delirium is a commonly occurring complex neuropsychiatric disorder. Evidence for its treatment based on randomized controlled trials (RCTs) is poor...
  4. ncbi Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes
    L Xiao
    Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, SK, Canada
    Mol Psychiatry 13:697-708. 2008
    ..These findings suggest a new neural mechanism of antipsychotic action of QUE, and help to establish a role for oligodendrocytes in the etiopathology and treatment of schizophrenia...
  5. ncbi Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex
    Satoshi Yamamura
    Department of Psychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, 2 174 Edobashi, Tsu, Mie, 514 8507, Japan
    Psychopharmacology (Berl) 206:243-58. 2009
    ..The atypical antipsychotic drug, quetiapine (QTP), is effective in schizophrenia and mood disorders, but induces seizures compared to typical antipsychotics...
  6. ncbi Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial
    Michael Liebowitz
    Department of Psychiatry, Columbia University, New York, New York 10128, USA
    Depress Anxiety 27:964-76. 2010
    ..evaluate the efficacy (time to recurrence of depressive symptoms) of once daily extended release quetiapine fumarate (quetiapine XR) as maintenance monotherapy treatment to prevent relapse for major depressive disorder (MDD)...
  7. ncbi Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors
    Yuko Tanibuchi
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1 8 1 Inohana, Chiba 260 8670, Japan
    Eur Neuropsychopharmacol 19:861-7. 2009
    ..Therefore, it is likely that antagonism at alpha(1)-adrenoceptors is involved in the mechanism underlying quetiapine's psychopharmacological action...
  8. ncbi Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial
    Roger S McIntyre
    Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Canada
    Eur Neuropsychopharmacol 15:573-85. 2005
    ..The primary efficacy outcome variable was change from baseline to Day 21 in Young Mania Rating Scale (YMRS) score...
  9. ncbi Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study
    Alexander McIntyre
    Department of Psychiatry, Penticton Regional Hospital, Penticton, British Columbia, Canada
    Depress Anxiety 24:487-94. 2007
    ..Further studies are warranted...
  10. ncbi Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
    Rene S Kahn
    Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, Netherlands
    Lancet 371:1085-97. 2008
    ..We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia...
  11. ncbi The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma
    Qian Bian
    Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi Higashi ku, Fukuoka, 812 8582, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 32:42-8. 2008
    ....
  12. ncbi Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
    ..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia...
  13. pmc Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol
    S E Purdon
    University of Alberta, Edmonton, Alta
    J Psychiatry Neurosci 26:137-49. 2001
    ..To assess the efficacy of quetiapine, a recently introduced second generation antipsychotic medication, in reducing cognitive impairment in patients with schizophrenia...
  14. ncbi Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study
    Robert A Riesenberg
    Atlanta Center for Medical Research, Atlanta, Georgia 30308, USA
    Clin Ther 34:2202-11. 2012
    ..A human-volunteer study reported lower sedation intensity during escalation of the extended-release formulation of quetiapine fumarate (quetiapine XR) than the immediate-release (IR) formulation...
  15. pmc Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials
    Narong Maneeton
    Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    BMC Psychiatry 12:160. 2012
    ..Schizophrenia and bipolar depression trials suggest that quetiapine may have an antidepressant effect...
  16. ncbi Quetiapine: a review of its use in the management of bipolar depression
    Mark Sanford
    Adis, Auckland, New Zealand
    CNS Drugs 26:435-60. 2012
    ..Further head-to-head trials of quetiapine versus other drug regimens that are effective in bipolar depression would be of considerable interest...
  17. ncbi Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial
    M A Katzman
    START Clinic for Mood and Anxiety Disorders, Canada
    J Anxiety Disord 22:1480-6. 2008
    ..Generalized anxiety disorder (GAD) is a chronic disorder associated with significant morbidity and disability. Traditional therapies are associated with poor levels of remission, and often result in troublesome side effects...
  18. ncbi Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study
    Richard Weisler
    Department of Psychiatry, University of North Carolina, Chapel Hill, Chapel Hill, NC, USA
    CNS Spectr 14:299-313. 2009
    ..Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy was evaluated in major depressive disorder (MDD)...
  19. ncbi Treatment options for bipolar depression: a systematic review of randomized, controlled trials
    Eduard Vieta
    Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Salud Mental, Barcelona, Spain
    J Clin Psychopharmacol 30:579-90. 2010
    ..Quetiapine and the olanzapine-fluoxetine combination showed the greatest symptomatic improvement. Efficacy considerations will need to be balanced against safety and tolerability of the individual agents...
  20. ncbi Metabolic effects of the atypical antipsychotics
    James Wooten
    South Med J 100:771-2. 2007
  21. ncbi Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322 4990, USA
    J Clin Psychiatry 63:5-11. 2002
    ..Finally, imaging studies with positron emission tomography confirm significant differences between quetiapine and typical antipsychotics that may be indicative of their differences in mechanism of action and propensity for producing EPS...
  22. ncbi A pilot trial of quetiapine for the treatment of patients with delirium
    Chi Un Pae
    Department of Psychiatry, Kangnam St Mary s Hospital, The Catholic University of Korea College of Medicine, Banpo dong, Seocho Gu, Seoul, South Korea
    Hum Psychopharmacol 19:125-7. 2004
    ..3% and 55.1%, respectively. Quetiapine was effective and safe for the treatment of patients with delirium, and could be a useful alternative agent to classical antipsychotics in the treatment of delirium...
  23. ncbi Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease
    Haiyun Xu
    Department of Anatomy, Southern Illinois University at Carbondale, IL, USA
    FEBS J 275:3718-28. 2008
    ....
  24. pmc Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone
    Erik Johnsen
    Division of Psychiatry, H aukeland University Hospital, Sandviken, PB 23, N 5812 Bergen, Norway
    BMC Psychiatry 10:26. 2010
    ....
  25. ncbi Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies
    Didier Meulien
    AstraZeneca Research and Development, Sodertalje, Sweden
    Hum Psychopharmacol 25:103-15. 2010
    ....
  26. ncbi Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study
    Kyoung Uk Lee
    Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Int Clin Psychopharmacol 20:311-4. 2005
    ..The present study shows that both amisulpride and quetiapine may be useful drugs for the treatment of delirium on the basis of effectiveness and relative lack of adverse events. Further systematic controlled studies are required...
  27. ncbi Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use
    Noah S Philip
    Butler Hospital and Department of Psychiatry and Human Behavior, The Warren Alpert Medical School at Brown University, Providence, RI 02906, USA
    Ann Clin Psychiatry 20:15-20. 2008
    ..To investigate such usage of quetiapine, we evaluated prescribing practices of this drug at our acute-care psychiatric hospital...
  28. pmc Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
    Christoph U Correll
    The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, United States
    Schizophr Res 89:91-100. 2007
    ..To determine whether the coprescribing of two or more antipsychotics, a relatively frequent practice with little data to support its safety and efficacy, is associated with an increased prevalence of metabolic syndrome...
  29. ncbi Newer treatment studies for bipolar depression
    Keming Gao
    NIMH Bipolar Research Center, Mood Disorders Program, University Hospitals of Cleveland Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Bipolar Disord 7:13-23. 2005
    ..Depressive symptoms of bipolar disorder have more negative impact on a patient's life than manic symptoms. This review focused on the emerging efficacy data for treatments in bipolar depression...
  30. ncbi Quetiapine addiction?
    Emil R Pinta
    Am J Psychiatry 164:174-5. 2007
  31. ncbi Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension
    Philip D Harvey
    University of Miami Miller School of Medicine, Miami, FL, USA Electronic address
    Eur Neuropsychopharmacol 23:1373-82. 2013
    ..These findings require replication, but are not due to practice effects, because of the placebo and active controls...
  32. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  33. ncbi The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature
    Bernard A Fischer
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Neurosci Biobehav Rev 34:555-8. 2010
    ..This includes the unwelcome possibility of restricting access to this effective medication...
  34. ncbi Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 164:1061-71. 2007
    ..The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis...
  35. ncbi Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:1186-94. 2007
    ..The primary objective of this double-blind study was to compare the effects of treatment initiation with risperidone and quetiapine on cognitive function in subjects with stable bipolar disorder...
  36. ncbi Tardive dyskinesia in a patient treated with quetiapine
    Emmanouil Rizos
    Second Department of Psychiatry, University of Athens, Medical School, Attikon General Hospital, Greece
    World J Biol Psychiatry 10:54-7. 2009
    ..Although, it is under consideration the possibility that the improvement could have been due to the discontinuation of quetiapine, we conclude that aripiprazole improved the TD symptoms...
  37. ncbi The role of atypical antipsychotics in the treatment of delirium
    Thomas L Schwartz
    Department of Psychiatry, S U N Y Upstate Medical University, Syracuse 13210, USA
    Psychosomatics 43:171-4. 2002
    ..g., schizophrenia or bipolar disorder), but few studies have evaluated them in the treatment of delirium. This paper reviews the pertinent literature and summarizes tentative guidelines for novel antipsychotic use in delirium...
  38. ncbi Possible intranasal quetiapine misuse
    Anna K Morin
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, 19 Foster Street, Worcester, MA 01608, USA
    Am J Health Syst Pharm 64:723-5. 2007
    ..A possible case of intranasal quetiapine misuse in a patient with schizoaffective disorder and substance abuse is presented..
  39. ncbi Quetiapine-induced myoclonus
    Latha Velayudhan
    Camden and Islington Mental Health and Social Care Trust, London, UK
    Int Clin Psychopharmacol 20:119-20. 2005
    ..These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effect of quetiapine...
  40. doi Addictive potential of quetiapine
    David Murphy
    Am J Psychiatry 165:918. 2008
  41. ncbi Quetiapine: another drug with potential for misuse? A case report
    Thomas Paparrigopoulos
    J Clin Psychiatry 69:162-3. 2008
  42. ncbi Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    Martin Dossenbach
    Eli Lilly and Company, Ges m b H, Kölblgasse 8 10, 1030 Vienna, Austria
    Eur Psychiatry 21:251-8. 2006
    ..This report will compare the effects of selected atypical and typical antipsychotics on sexual function in a large, international population of outpatients with schizophrenia who were treated over 1 year...
  43. ncbi A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder
    Charles L Bowden
    Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 66:111-21. 2005
    ..To evaluate the efficacy and tolerability of quetiapine monotherapy versus placebo for the treatment of mania associated with bipolar disorder...
  44. ncbi Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease
    Jue He
    Laboratory of Neuropharmacology, Wenzhou Medical College, Wenzhou, PR China
    Neurobiol Aging 30:1205-16. 2009
    ....
  45. ncbi N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity
    Niels H Jensen
    Department of Pharmacology, University of North Carolina Medical School, Chapel Hill, NC 27599, USA
    Neuropsychopharmacology 33:2303-12. 2008
    ..Possible contributions of this metabolite to the side effects of quetiapine are discussed...
  46. ncbi Quetiapine regulates neurogenesis in ischemic mice by inhibiting NF-kappaB p65/p50 expression
    Xiaoying Bi
    Department of Neurology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China
    Neurol Res 31:159-66. 2009
    ..Previously, we showed that quetiapine, an atypical antipsychotic drug, significantly attenuated neurodegeneration induced by global cerebral ischemia (GCI). The present work investigates the effects of quetiapine on neurogenesis...
  47. ncbi A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression
    Joseph R Calabrese
    University Hospitals of Cleveland and Case University School of Medicine, 11400 Euclid Ave, Suite 200, Cleveland, OH 44106, USA
    Am J Psychiatry 162:1351-60. 2005
    ..There is a major unmet need for effective options in the treatment of bipolar depression...
  48. ncbi Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study
    G Sachs
    Harvard Bipolar Research Program, Massachusetts General Hospital, Boston, 02114, USA
    Bipolar Disord 6:213-23. 2004
    ..Evaluate the efficacy and tolerability of quetiapine (QTP) combined with lithium (Li) or divalproex (DVP) in the treatment of acute mania...
  49. ncbi Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder
    H N Wang
    Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi an, Shaanxi, China
    Physiol Res 59:263-71. 2010
    ..QUE has preventive and protective effects against stress-associated symptoms and the changes in pERK1/2 functions may be associated with the pathophysiology of traumatic stress and the therapeutic efficacy of anti-PTSD therapy...
  50. ncbi Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice
    Bin Yan
    Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, A114 Medical Research Bldg, 103 Wiggins Road, Saskatoon, Canada
    Life Sci 81:353-61. 2007
    ..The results suggest that quetiapine may have defending effects on the impairments induced by cerebral ischemia, which enhances our understanding about the mechanisms of quetiapine...
  51. ncbi Quetiapine: efficacy, tolerability and safety in schizophrenia
    Chanoch Miodownik
    University of the Negev, Division of Psychiatry, Faculty of Health Sciences Ben Gurion, Be er Sheva, Israel
    Expert Rev Neurother 6:983-92. 2006
    ..There are also continued efforts to understand, predict and manage the side-effect risk with quetiapine...
  52. ncbi A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium
    Yukiya Sasaki
    Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    J Clin Psychiatry 64:1316-21. 2003
    ..The purpose of the present open-label, flexible-dose study was to provide preliminary data on the usefulness and safety of quetiapine for patients with delirium...
  53. pmc Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment
    Nurith Amitai
    Department of Psychiatry, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA
    Pharmacol Biochem Behav 93:248-57. 2009
    ....
  54. ncbi The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats
    Jue He
    Laboratory of Neuropharmacology, Wenzhou Medical College, Wenzhou, China
    Behav Brain Res 168:236-42. 2006
    ..These results suggest that quetiapine may have ameliorating effects on the cognitive impairment and brain apoptotic processes induced by PCP...
  55. ncbi Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature
    Lara A Ray
    Department of Psychology, University of California, Los Angeles, CA 90095 1563, USA
    Drug Alcohol Rev 29:568-75. 2010
    ....
  56. ncbi An open-label study of quetiapine for delirium
    Benchalak Maneeton
    Department of Psychiatry, Chiang Mai University, Chiang Mai, Thailand
    J Med Assoc Thai 90:2158-63. 2007
    ..To evaluate the effects of quetiapine treatment in patients with delirium...
  57. ncbi An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms
    Kristina Timdahl
    AstraZeneca, Sodertalje, Sweden
    Hum Psychopharmacol 22:315-25. 2007
    ....
  58. ncbi Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study
    Sara I J Schutters
    J Clin Psychiatry 66:540-2. 2005
  59. ncbi The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia
    Lei Chen
    Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
    Value Health 11:34-43. 2008
    ..Using data in real-world clinical practice, this study aims to compare the health-care use patterns of patients with schizophrenia who use oral antipsychotics...
  60. ncbi Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes
    Lili C Kopala
    Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    Schizophr Res 81:29-39. 2006
    ..The first episode of a psychotic disorder provides a unique opportunity to initiate optimal treatment but when a new medication becomes available, little data exist to guide the appropriate use in this population...
  61. ncbi Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors
    David E Adson
    Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota 55454 1495, USA
    Depress Anxiety 19:121-6. 2004
    ..Given the open-label design of the trial, more rigorous studies are clearly indicated...
  62. ncbi Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients
    Gry Vibeke Bakken
    vCenter for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
    Ther Drug Monit 33:222-6. 2011
    ....
  63. ncbi Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia
    Siegfried Kasper
    Department of General Psychiatry, Medical University Vienna, Vienna, Austria
    Int Clin Psychopharmacol 19:281-9. 2004
    ..In conclusion, quetiapine may be a suitable therapy in the long-term treatment of schizophrenia...
  64. ncbi Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?
    Rebecca C Rossom
    Department of Psychiatry, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA
    J Am Geriatr Soc 58:1027-34. 2010
    ..To estimate mortality risk associated with individual commonly prescribed antipsychotics...
  65. ncbi Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine
    Damiaan Denys
    Department of Psychiatry, The Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Psychopharmacology (Berl) 176:195-203. 2004
    ....
  66. ncbi Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis
    K P Good
    Department of Psychiatry, Dalhousie University, Suite 3073 AJLB, 5909 Veterans Memorial Lane, Halifax, Nova Scotia, Canada B3H 2E2
    Br J Psychiatry Suppl 43:s45-9. 2002
    ..The efficacies of second-generation antipsychotic medications in reducing symptoms are reasonably well-documented, but their effects on cognition are less clearly understood...
  67. ncbi Dosing and switching strategies for quetiapine fumarate
    Andrew J Cutler
    Coordinated Research of Florida, Inc, Winter Park 32789, USA
    Clin Ther 24:209-22. 2002
    ..The atypical antipsychotic agent quetiapine fumarate has demonstrated efficacy and tolerability in clinical trials in patients with chronic or subchronic exacerbations of schizophrenic symptoms...
  68. ncbi Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)
    Michael E Thase
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
    J Clin Psychopharmacol 26:600-9. 2006
    ..This study demonstrates that quetiapine monotherapy is an effective and well-tolerated treatment for depressive episodes in bipolar disorder, confirming the results observed from a previous study (BipOLar DEpRession [BOLDER] I)...
  69. ncbi Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
    N Mohr
    MRC Unit on Anxiety Disorders, University of Stellenbosch, Tygerberg, Cape Town, South Africa
    Int Clin Psychopharmacol 17:37-40. 2002
    ..Quetiapine, a relatively well tolerated agent, deserves further controlled study in this context...
  70. ncbi Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse
    Yanbo Zhang
    Department of Psychiatry, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
    Schizophr Res 106:182-91. 2008
    ..These results suggest that the CPZ-exposed C57BL/6 mouse is a potential animal model to study possible roles of OLs in the pathogenesis and treatment of schizophrenia...
  71. ncbi Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism
    Junji Ichikawa
    Division of Psychopharmacology, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Brain Res 956:349-57. 2002
    ..However, 5-HT(1A) agonism may be important only for quetiapine-induced ACh release...
  72. ncbi A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia
    Neil D Woodward
    Department of Psychology, Vanderbilt University, Nashville, TN 37203, USA
    Int J Neuropsychopharmacol 8:457-72. 2005
    ..Atypical antipsychotics produce a mild remediation of cognitive deficits in schizophrenia, and specific atypicals have differential effects within certain cognitive domains...
  73. ncbi Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release
    Carlos Figueroa
    Research Strategy International, Torrance, CA, USA
    Prog Neuropsychopharmacol Biol Psychiatry 33:199-204. 2009
    ....
  74. ncbi Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects
    Catherine Datto
    AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850, USA
    Clin Ther 31:492-502. 2009
    ..The tolerability of the 2 formulations was also evaluated...
  75. ncbi Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression
    Igor Galynker
    J Clin Psychiatry 66:544. 2005
  76. ncbi Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study
    Brian Bortnick
    Comprehensive NeuroScience, Atlanta, GA 30342, USA
    J Affect Disord 128:83-94. 2011
    ..Evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) once-daily monotherapy for patients with major depressive disorder (MDD)...
  77. ncbi Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics
    Stephan Heres
    Klinik und Poliklinik für Psychiatrie und Psychotherapie der Technischen Universität München am Klinikum rechts der Isar, Moehlstrasse 26, 81675 Munich, Germany
    Am J Psychiatry 163:185-94. 2006
    ....
  78. ncbi The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats
    Jue He
    Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, 103 Wiggins Road, Saskatoon, Sask, Canada S7N 5E4
    Behav Brain Res 172:39-45. 2006
    ..These findings suggest that quetiapine may have therapeutic effects in the treatment of cognitive impairment and neurodegeneration induced by METH...
  79. ncbi Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia
    Michael Riedel
    Dept of Psychiatry and Psychotherapy, Ludwig Maximilians University of Munich, Nussbaumstrasse 7, 80336 Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 257:402-12. 2007
    ..Furthermore, quetiapine produced a significantly greater improvement in reaction quality/attention than olanzapine...
  80. ncbi Quetiapine for bipolar depression: a systematic review and meta-analysis
    Alberto Chiesa
    Institute of Psychiatry, University of Bologna, Bologna, Italy
    Int Clin Psychopharmacol 27:76-90. 2012
    ..Furthermore, several clinical variables moderated outcomes under investigation. In conclusion, quetiapine could have some advantages over traditional treatments for the treatment of bipolar depression...
  81. ncbi Antipsychotics for the prevention and treatment of delirium in the intensive care unit: what is their role?
    John W Devlin
    Northeastern University School of Pharmacy, Boston, MA 02115, USA
    Harv Rev Psychiatry 19:59-67. 2011
    ..A research framework for future evaluation of the use of antipsychotic therapy in the critically ill is proposed...
  82. ncbi A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder
    Arifulla Khan
    Northwest Clinical Research Center, Bellevue, WA 98007, USA
    J Clin Psychopharmacol 31:418-28. 2011
    ..Quetiapine XR (50/150 mg/d) monotherapy was effective at week 8 in patients with GAD; symptom improvement was seen at week 1 for all doses (50/150/300 mg/d). Safety and tolerability were consistent with the known profile of quetiapine...
  83. ncbi Quetiapine. A review of its use in the management of schizophrenia
    Susan M Cheer
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:173-99. 2004
    ..Overall, quetiapine has an excellent risk/benefit profile and is a suitable first-line option for the treatment of schizophrenia...
  84. ncbi Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone
    Ilkka Larmo
    Keskinen Terveyskeskus, Auroran Psykiatrinen Osasto, Helsingin kaupunki, Finland
    Hum Psychopharmacol 20:573-81. 2005
    ..001 vs baseline). Switching to quetiapine produced efficacy and tolerability benefits regardless of whether their previous antipsychotic was haloperidol, olanzapine or risperidone...
  85. ncbi Atypical antipsychotics in bipolar depression: potential mechanisms of action
    Lakshmi N Yatham
    Department of Psychiatry, The University of British Columbia, UBC Hospital, Vancouver, Canada
    J Clin Psychiatry 66:40-8. 2005
    ..Further studies should be conducted to examine these hypotheses...
  86. ncbi Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    J Clin Psychopharmacol 24:599-606. 2004
    ..Quetiapine, in combination with lithium or divalproex, is well tolerated and has superior efficacy to lithium or divalproex alone in the treatment of bipolar mania...
  87. pmc Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Med 3:21. 2005
    ..Stopping antipsychotic treatment can interrupt improvement and exacerbate the illness. The reasons for discontinuing treatment during controlled clinical trials were analyzed to explore this phenomenon...
  88. ncbi Quetiapine extended release: in schizophrenia
    Claudine M Baldwin
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    CNS Drugs 23:261-9. 2009
    ..Rates of worsening of Simpson-Angus Scale and Barnes Akathisia Rating Scale scores were not dissimilar among quetiapine XR, quetiapine immediate release and placebo...
  89. ncbi Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia
    Robin A Emsley
    Department of Psychiatry, Faculty of Medicine, University of Stellenbosch, Tygerberg, Cape Town, South Africa
    J Psychopharmacol 17:210-5. 2003
    ..These findings extend the evidence for an antidepressant effect for the novel antipsychotics in schizophrenia, and suggest that this is not limited to acutely psychotic patients...
  90. ncbi Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade
    Sitra Tauscher-Wisniewski
    Schizophrenia and Continuing Care Program, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychiatry 63:992-7. 2002
    ..We treated patients experiencing their first episode of schizophrenia with a single daily dose of quetiapine to achieve a transient daily peak of D(2) receptor blockade, to determine if this would lead to an antipsychotic response...
  91. ncbi Clinical pharmacokinetics of quetiapine: an atypical antipsychotic
    C L DeVane
    Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425, USA
    Clin Pharmacokinet 40:509-22. 2001
    ..Subsequent clinical studies of the plasma concentration versus effect relationships for quetiapine may help to further define guidelines for dosage regimen design...
  92. ncbi A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors
    Damiaan Denys
    Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
    J Clin Psychiatry 65:1040-8. 2004
    ..This study was conducted to evaluate the efficacy and tolerability of quetiapine in addition to an SRI for treatment-refractory patients with OCD...
  93. ncbi Quetiapine-induced leucopenia: possible dosage-related phenomenon
    Oloruntoba Oluboka
    Can J Psychiatry 48:65-6. 2003
  94. ncbi Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study
    M Atmaca
    Firat University, Medical Faculty Hospital, Department of Psychiatry, Elazig, Turkey
    Int Clin Psychopharmacol 17:115-9. 2002
    ..The addition of quetiapine to ongoing SRI therapy has been found to be effective and well-tolerated approach in patients with refractory OCD...
  95. ncbi Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:453-61. 2006
    ..Greater improvement in positive symptoms and a greater study completion rate may hold relevance to enhanced functional outcomes observed after OLZ therapy...
  96. pmc Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
    Douglas Faries
    Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Psychiatry 5:26. 2005
    ..This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications...
  97. ncbi A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania
    Melissa P DelBello
    Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0559, USA
    J Am Acad Child Adolesc Psychiatry 41:1216-23. 2002
    ..It was hypothesized that DVP in combination with quetiapine would be more effective than DVP alone for treating mania associated with adolescent bipolar disorder. Furthermore, it was hypothesized that quetiapine would be well tolerated...
  98. ncbi Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years
    Gregor E Berger
    The Schloessli Clinic, Department of Research and Education, Schlösslistrasse 8, CH 8618 Oetwil am See, Switzerland
    J Clin Psychiatry 69:1702-14. 2008
    ..To assess dosing, efficacy, and tolerability of quetiapine fumarate in drug-naive first-episode psychosis...
  99. ncbi Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study
    Damiaan Denys
    Department of Psychiatry, University Medical Center, Utrecht, The Netherlands
    J Clin Psychiatry 63:700-3. 2002
    ..The objective of this study was to examine whether addition of the atypical antipsychotic quetiapine to SRIs is useful for patients with OCD who do not respond to SRI monotherapy...
  100. ncbi Is leukopenia associated with divalproex and/or quetiapine?
    Preetha Nair
    Psychosomatics 46:188-9. 2005
  101. ncbi Quetiapine augmentation in depressed patients with partial response to antidepressants
    James S Olver
    Department of Psychiatry, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
    Hum Psychopharmacol 23:653-60. 2008
    ..We aim to investigate the efficacy and tolerability of augmentation with quetiapine in depressed patients with a partial response to antidepressants...

Research Grants68

  1. Transdisciplinary Imaging Genetics Center (1 of 2)(RMI)
    Steven Potkin; Fiscal Year: 2006
    ..The new knowledge generated by the Center holds considerable promise for improving diagnosis and treatment of mental illness. [unreadable] [unreadable]..
  2. Norepinephrine Transporters: Targets for ADHD
    FRANK TARAZI; Fiscal Year: 2004
    ..Expected findings should lead to novel compounds that can be developed as much needed innovative non-stimulant treatments for ADHD and other major neuropsychiatric disorders. ..
  3. Hybrid Drugs: Novel Pharmacotherapy for ADHD
    FRANK TARAZI; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  4. Effects of antipsychotic drugs on brain and behavior
    FRANK TARAZI; Fiscal Year: 2005
    ..adult rats, and should evolve new principles for improved treatments for childhood-onset schizophrenia and other major pediatric psychiatric disorders. ..
  5. TREATMENT OF EARLY ONSET SCHIZOPHRENIA SPECTRUM (TEOSS)
    Robert Findling; Fiscal Year: 2005
    ..This study will provide information about the comparative effectiveness of the most commonly used and representative antipsychotic drugs in youth with schizophrenia spectrum disorders. ..
  6. Novel pharmacotherapies for treatment of ADHD
    FRANK TARAZI; Fiscal Year: 2003
    ..Expected findings should evolve new principles and lead to novel compounds that can be used as much-needed innovative treatments for ADHD and other major neuropsychiatric disorders. ..
  7. MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT
    Matthew Byerly; Fiscal Year: 2006
    ..abstract_text> ..
  8. Bipolar II Depression: Lithium, SSRI, or the Combination
    Trisha Suppes; Fiscal Year: 2010
    ..We also hypothesize that the frequency of side effects will be significantly less in patients on SSRI monotherapy. Thus, secondary aims include assessment of patient satisfaction, which may affect compliance in the clinical setting. ..
  9. Compensating for Cognitive Deficits in Schizophrenia
    Dawn Velligan; Fiscal Year: 2005
    ..abstract_text> ..
  10. MEDICATION ADHERENCE AND OUTCOMES IN SCHIZOPHRENIA
    Dawn Velligan; Fiscal Year: 2004
    ..Moreover, we hypothesize that compliance and functioning will return to baseline levels six months after discontinuation of treatment. ..
  11. Brain Abnormalities in Adolescent Bipolar Disorder
    Melissa Delbello; Fiscal Year: 2006
    ..The research conducted will advance our understanding of the neurophysiology of BPD. ..
  12. EFFECTIVENESS OF INVOLUNTARY OUTPATIENT COMMITMENT
    Marvin Swartz; Fiscal Year: 2002
    ..abstract_text> ..
  13. Interventions for Adherence to Oral Antipsychotic Medications in Schizophrenia
    DAWN IRENE VELLIGAN; Fiscal Year: 2010
    ..The public health implications include effective disease management, maximizing long-term outcomes, and containing health care costs for schizophrenia. ..
  14. Topiramate for Co-occurring Cannabis Use and Bipolar Disorders in Adolescents
    Melissa Delbello; Fiscal Year: 2008
    ..The preliminary data from this projectwill inform and guide the design of future larger, more definitive, controlled studies of topiramate as a treatment for adolescent substance use disorders. ..
  15. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael E Thase; Fiscal Year: 2010
    ....
  16. CENTER FOR RESEARCH IN OLDER PEOPLE WITH PSYCHOSES
    Dilip Jeste; Fiscal Year: 2006
    ....
  17. Neural basis of heritable DA-mediated gating deficits
    Neal R Swerdlow; Fiscal Year: 2010
    ....
  18. Neuroscience at the Boundaries of Neurology and Psychiatry
    Neal Swerdlow; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  19. Schizophenia Libility Genes among African-Americans
    Joseph McEvoy; Fiscal Year: 2006
    ..Finally, we have an outstanding track record of African American participation in research studies, and a deep appreciation of their population genetics. ..
  20. Auditory Perception of Drug Names: Neighborhood Effects
    Bruce Lambert; Fiscal Year: 2006
    ..abstract_text> ..
  21. Depression in Alzheimer's Disease Study 2 (DIADS-2)
    Lon Schneider; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  22. CORTICO-STRIATAL SUBSTRATES OF DEFICIENT STARTLE GATING
    Neal R Swerdlow; Fiscal Year: 2010
    ..New information from these studies will be a foundation for innovative models of the pathophysiology of schizophrenia and other inherited neuropsychiatric disorders, and for prospective strategies for novel drug development. ..
  23. Course of Functional Deficits in Late-Life Schizophrenia
    Philip Harvey; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  24. Metabolic Effects of Newer Antipsychotics in Older Pts
    Dilip Jeste; Fiscal Year: 2009
    ..abstract_text> ..
  25. A Simple Measure for Studying Sensory Gating Deficits
    Neal Swerdlow; Fiscal Year: 2007
    ..abstract_text> ..
  26. Addressing Challenges in Schizophrenia Research
    THOMAS STROUP; Fiscal Year: 2007
    ..The applicant's career will focus on designing and testing interventions to improve outcomes of persons who are severely affected by schizophrenia. ..
  27. DVD Consent for Research in Older Schizophrenia Patients
    Dilip Jeste; Fiscal Year: 2008
    ..The DVD-based consent is not intended to supplant, but rather to supplement, the researcher-participant in-person interaction involved in consent process. ..
  28. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2008
    ..This will be an important step for improving the lives of people with schizophrenia. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  29. COMT genotype and response to cognitive remediation in schizophrenia
    Jean Pierre Lindenmayer; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  30. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006
    ..Alcohol use is the primary outcome, and alcohol craving is the secondary outcome. Manic and depressive symptom severity and the relationship between changes in alcohol use and changes in mood will be expIored. ..
  31. Combination Therapy in Bipolar Rapid Cycling
    Joseph Calabrese; Fiscal Year: 2004
    ....
  32. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
    ....
  33. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  34. NEUROLEPTIC-INDUCED MOVEMENT DISORDERS IN OLDER PATIENTS
    Dilip Jeste; Fiscal Year: 2003
    ..We believe that our findings will have major therapeutic implications for the use of antipsychotics, particularly in older patients. ..
  35. Chinese Exercise Modalites in Parkinson's Disease
    Jorge Juncos; Fiscal Year: 2003
    ..A better understanding of exercise-induced neural plasticity and motor control would offer a significant, and heretofore unexploited rehabilitative potential in PD. ..
  36. Neuroimaging of Children at Risk for Biopolar Disorder
    Kiki Chang; Fiscal Year: 2006
    ..Chang plans to become an independent investigator in the field of pediatric BD and thus contributing to the current knowledge of the neurobiology and development of BD. ..
  37. Treating Depressed Mothers in a Community Clinic
    Holly Swartz; Fiscal Year: 2006
    ..The skills, training, and pilot data obtained from this award will subsequently support the Candidate's development of an R01 application in Years 03-05 of the award period. ..
  38. NEURAL CIRCUITRY OF SENSORIMOTOR GATING ACROSS SPECIES
    Neal Swerdlow; Fiscal Year: 2006
    ....
  39. LATE ONSET SCHIZOPHRENIA--A NEUROPSYCHIATRIC STUDY
    Dilip Jeste; Fiscal Year: 2002
    ..g., MRI quantitative analysis, outcome and functioning measures) to the new questions being asked. Our studies should have a major impact on the understanding of schizophrenia and aging. ..
  40. Cardiac-Related Mortality with Atypical Antipsychotics
    DEANNA KELLY; Fiscal Year: 2005
    ..This study is important as data on long-term health outcomes with atypical antipsychotics is lacking from the literature. ..
  41. ADJUNCTIVE ACUPUNCTURE TO TREAT BIPOLAR DEPRESSION
    PATRICIA SUPPES; Fiscal Year: 2002
    ..Should acupuncture demonstrate efficacy in the treatment of bipolar disorder, further studies will be proposed to evaluate its utility for maintenance and prevention. ..
  42. Divalproex and Placebo, Lithium, or Quetiapine for Mania
    Trisha Suppes; Fiscal Year: 2008
    ..abstract_text> ..
  43. Acute Treatment of Bipolar II Depression
    PATRICIA SUPPES; Fiscal Year: 2005
    ..This pilot study will provide data addressing the aims and sample size needed for a full-scale intervention trial. ..
  44. Bipolar Disorder in Pregnancy: Predictors of Morbidity
    DONALD NEWPORT; Fiscal Year: 2009
    ..Furthermore, the novel PK data will expand our understanding of prenatal drug metabolism, and the project will establish a cohort of children of women with BPD with detailed prospective prenatal histories. ..
  45. KAN-DO: A Family-Based Intervention to Prevent Childhood Obesity
    Truls Ostbye; Fiscal Year: 2010
    ..Participants will be surveyed at baseline (3 months postpartum), 12 and 24 months post-baseline. Extended follow-up will enable evaluation of long-term benefits, and if effective, the KAN-DO intervention can be disseminated broadly. ..
  46. Antipsychotics and Mortality in Older Patients
    HELEN KALES; Fiscal Year: 2009
    ..The results of this study will be of immediate relevance to clinicians and policymakers. ..
  47. Acoustic startle reduction in cocaine dependence
    Erica Duncan; Fiscal Year: 2009
    ..abstract_text> ..
  48. Depressoin in Alzheimer's Disease Study-2 (DIADS-2)
    Jacobo Mintzer; Fiscal Year: 2007
    ..abstract_text> ..
  49. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILIZER TRIAL
    RUSSELL SCHEFFER; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  50. Topiramate for alcohol and cocaine dependence
    Kyle Kampman; Fiscal Year: 2008
    ..abstract_text> ..
  51. Treatment with Exercise Augmentation for Depression
    Madhukar Trivedi; Fiscal Year: 2006
    ....
  52. REVAMP Follow-Up
    Madhukar Trivedi; Fiscal Year: 2008
    ....
  53. PGP Regulation of Antipsychotic Exposure and Effects
    C Devane; Fiscal Year: 2008
    ..The results of this research will provide support for translational studies in humans to refine treatment guidelines for the use of this class of medications in severely mentally ill patients. ..
  54. Psychiatric Research Education Program(PREP)
    Carol Tamminga; Fiscal Year: 2007
    ..Together, these features place the UTSWMC Department of Psychiatry in an ideal position to stimulate and train the next generation of basic and clinical psychiatric researchers. ..
  55. TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC
    Scott Woods; Fiscal Year: 2004
    ..The existence of a previous sample at the same site provides a useful additional comparison group. Methods including sample ascertainment and TD assessment are closely modeled after the original work. ..
  56. ELEMENTARY SCHOOL NEUROSCIENCE LITERACY
    Gary Duncan; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  57. DEPRESSION DIAGNOSIS AND TREATMENT IN PARKINSON DISEASE
    Daniel Weintraub; Fiscal Year: 2008
    ..abstract_text> ..
  58. Racial Differences in Geriatric Antidepressant Adherence
    HELEN KALES; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  59. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  60. MOLECULAR NEUROBIOLOGY OF DEPRESSION
    Richard Shelton; Fiscal Year: 2003
    ..Develop further expertise in basic molecular biological methods; 2. Develop new projects oriented to future funding opportunities; and 3. Continue to mentor the next generation of investigators. ..
  61. Models of Antipsychotic Prophylaxis for Schizophrenia
    Susan Powell; Fiscal Year: 2005
    ..3. To assess the effects of prophylactic antipsychotic treatment on neonatal ventral hippocampal lesion induced behavioral deficits. ..
  62. Enhancing the Prospective Prediction of Psychosis
    Diana Perkins; Fiscal Year: 2007
    ..Each site has proven its ability to recruit prodromal patients in a previous collaboration. ..
  63. Novel Pharmacological Strategies in Autism
    Christopher McDougle; Fiscal Year: 2009
    ..Phase II (following 6 months of aripiprazole monotherapy). ..
  64. GSK3: Neural Modulators and Mood Disorders
    Xiaohua Li; Fiscal Year: 2009
    ..This research is expected to provide significant new insight into the pathophysiology and the treatment of mood disorders. ..
  65. Neurophysiology of Working Memory in Bipolar Disorder
    Caleb Adler; Fiscal Year: 2007
    ..abstract_text> ..
  66. Treating Agitation/Psychosis in Dementia/Parkinsonism
    Roger Kurlan; Fiscal Year: 2004
    ..This study will provide important information regarding the optimal treatment of psychosis and agitation for patients with the commonly encountered combination of primary dementia and parkinsonism. ..